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 Abstract  Fostering innovation for the bene fi t of society is part of the mission of 
Stanford’s Of fi ce of Technology Licensing (OTL); “To promote the transfer of 
Stanford technology for society’s use and bene fi t while generating unrestricted 
income to support research and education.” Throughout Stanford’s history, research-
ers’ drive to innovate formed Stanford into the active and prominent academic insti-
tution that it is today. To help understand the role of Stanford’s OTL in this system, 
this chapter reviews OTL’s history, policies, and practices. We provide some attri-
butes that help OTL be successful in transferring technologies that will bene fi t the 
public, as well as examples of how OTL works with startups to move the technolo-
gies out from Stanford into companies. These companies might then produce new 
products that will bene fi t the world. 
 1  Stanford’s Background 
 Stanford’s history is steeped in innovation. One of the people who seeded and 
formed our university’s ecosystem and surrounding environment is Frederick 
Terman, former Professor, Dean, and Provost of the university. Professor Terman 
had a long history with Stanford, having moved to the university when his father 
took a faculty position. Following in his father’s professorial footsteps, he even-
tually became a faculty member at Stanford in the Electrical Engineering 
Department. 
 Professor Terman realized that California did not have many jobs for engineering 
graduates, so he helped to provide and build opportunities for such jobs, including 
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making Stanford and the surrounding area a premier place to be. First, he established 
the “steeples of excellence” practice whereby the university recruited leading pro-
fessors, which in turn attracted the notice of other important and rising academics. 
Second, he encouraged and helped students and former students to start businesses. 
One of the more famous examples is that of David Packard and William Hewlett. 
Third, he supported the development of the area surrounding Stanford for industry. 
One area developed was the Stanford Industrial Park (now called the Stanford 
Research Park), a high-technology park on Stanford’s land. 
 Stanford is presently a medium-sized university with 1,934 faculty members and 
over 15,000 students. Of our $4.1 billion budget, $1.2 billion is for sponsored 
research. The vast majority of the sponsorship for research at Stanford comes from 
the federal government of the United States (for example, the National Institutes of 
Health and the National Science Foundation). It has an endowment of around $16.5 
billion and part of the investment return from the endowment is used to support 
Stanford’s operating expenses. Stanford has seven schools—Business, Earth 
Sciences, Education, Engineering, Humanities and Sciences, Law, and Medicine. 
The majority of inventions that Stanford’s Of fi ce of Technology Licensing (OTL) 
handles come from Engineering, Humanities and Sciences, and Medicine, although 
we do receive a few from the other schools as well. 
 There are many ways Stanford transfers its knowledge and innovations to the 
world. Intrinsically, the education of students who go on to other endeavors is one 
of the main ways this happens. The publications, seminars, and presentations that 
the students, faculty, and other researchers give disseminate their  fi ndings. Stanford 
also has a faculty consulting policy where faculty are allowed to consult outside of 
the university 1 day per week  [ 1 ,  2 ] , using their knowledge to help companies pros-
per. There is also, of course, the licensing of the intellectual property owned by the 
university, the focus of this chapter. 
 2  Of fi ce of Technology Licensing 
 The mission of Stanford’s OTL is to promote the transfer of Stanford’s technology 
for society’s use and bene fi t while generating unrestricted income to support 
research and education. We put a large emphasis on “society’s use and bene fi t.” We 
do not license our technologies simply to gain income. Our exclusive licenses all 
include diligence to make sure a technology is not shelved, and we can terminate 
licenses if a company is not being diligent. Our goal is to have the technology devel-
oped and people’s lives improved. Although the majority of technologies do not 
actually become products or services, we provide the chance for it to happen. 
 The types of technologies we handle include patents, copyrightable material 
(including software), and biological material, such as cell lines, antibodies, and 
transgenic mice. The typical life cycle of a technology is:
 (a)  New technology created, often with support from government or other funding 
sources 
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 (b)  The technology is disclosed to OTL 
 (c)  OTL makes the decision whether to pursue the invention, which may include 
starting the patent process 
 (d)  OTL markets the invention 
 (e)  A company is founded to license the technology (licensee), or possibly many 
companies are founded 
 (f)  Licensing of the technology 
 (g)  Monies come in to support further research and education at the university 
 (h)  The cycle continues 
 This is not a self-sustaining cycle, and we do not know of a university where it 
is. As mentioned previously, the current amounts for sponsored research at Stanford 
are $1.2 billion. Last year, OTL brought in $66.8 million. OTL licenses between 
20% and 25% of the invention disclosures it receives. 
 3  Stanford’s Inventions 
 Our of fi ce was started in 1970 (after the era of local startups such as Hewlett-Packard 
and Varian). From the early days we had a number of interesting technologies. One 
of the  fi rst was FM Sound Synthesis developed by John Chowning. The FM Sound 
Synthesis technology allowed digital synthesizers to make new and interesting 
sounds. Yamaha saw the opportunity with this technology and licensed it from 
Stanford. It was the beginning of a long relationship that has lasted well after the 
initial patent expired in 1995. 
 In 1974, two researchers published an article on a method for recombinant DNA 
cloning. The director of OTL at the time read about the research and contacted the 
Stanford researcher, Stanley Cohen, about pursing patenting and commercialization 
of the technology. Eventually, this was done in cooperation with the University of 
California–San Francisco and its researcher, Herbert Boyer. Recombinant DNA 
went on to become a university licensing success story; it was licensed by over 400 
companies, brought in over $250 million in royalties, and was used in numerous 
products. These included human insulin, which was developed by Genentech, a 
company founded in part by Dr Boyer. The bene fi ts to humans and animals around 
the world from recombinant DNA technology have been enormous. 
 We have had inventions that were used in the DSL standards, production of 
monoclonal antibody drugs, microarrays, and the original algorithm for Google. 
The majority of our licenses are in the biotechnology  fi eld (for example, in our 2010 
 fi scal year, we signed 71 licenses in the biomedical space and 18 in the physical 
sciences). Going by the number of inventions licensed over our history, we licensed 
more inventions in the physical sciences. Of the 1,445 invention disclosures that 
OTL licensed, 560 were solely from biomedicine, 713 solely from the physical sci-
ences, and 172 from both the medical and physical sciences areas. Large sponsored 
research programs from the physical sciences account for much of this discrepancy. 
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For example, if just one particularly large program is removed from that list, the 
number of inventions licensed in the physical sciences drops to approximately the 
same number as our biomedical innovations. 
 This makes sense because in the biotechnology  fi eld large portfolio licenses are 
uncommon as typically only a few to several patents are associated with a product. 
In high tech, thousands of patents often cover a single product. 
 4  OTL by Numbers 
 In our  fi rst year of existence, OTL had 28 invention discloses, signed 3 licenses, and 
brought in royalties of $50,000. In FY2011 (our  fi scal year ends on August 31), we 
received 504 invention disclosures, signed 101 licenses, and brought in $66.8 mil-
lion in royalties. 
 Working on all of these activities are 38 staff members, including our director; 20 
associates and liaisons on the licensing side; 6 industrial contracts of fi cers (handling 
sponsored research, material transfer agreements, collaborations, and other types of 
agreements from industry); a patent agent; a few accounting personnel; and IT, 
compliance, and administrative staff members. 
 When Stanford receives royalties (payments) from its licensing activities, the 
monies are distributed as follows:
 (a)  OTL takes 15% off the top—these monies pay for our activities (e.g., salaries, 
rent, travel, computers, and IT services). Our patent expenses are not paid for 
from this amount, except in the case of write-offs. Instead, the patent expenses 
are originally paid for by the university general fund, which OTL repays if and 
when the invention is licensed. 
 (b)  After the 15%, we deduct any expenses remaining on the docket. Usually, these 
are the patent expenses. 
 (c)  The remainder is divided into thirds:
 1/3 to the inventors  –
 1/3 to the inventors’ department(s)  –
 1/3 to the inventors’ school(s)  –
 Our default for the inventors’ shares is to divide it equally between the inventors 
unless they agree and tell us otherwise. We do not make apportionment decisions 
because the inventors are the ones who know who did what work, but in general we 
think it is easiest and creates the least con fl ict when each inventor receives an equal 
share of the inventor royalties. 
 Figure  7.1 illustrates OTL’s income over time. Typically, it takes 10–15 years 
for any signi fi cant revenue to return to the university on one of its inventions. 
Our of fi ce  fi rst broke even for a single  fi scal year 10 years after its founding. We 
came out of the red completely in 1985. Much of the reason we became self-
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sustaining is that a few technologies, particularly recombinant DNA technology 
and FM Sounds, were bringing in enough income to cover all of our of fi ce 
expenses (e.g., salaries, resources). Historically, Stanford’s Departments of 
Genetics and Medicine have been especially proli fi c in the technology develop-
ment and licensing area. 
 Figure  7.1 shows hitting of our  fi rst revenue “cliff” in the late 1990s. This is 
when the Cohen–Boyer recombinant DNA cloning technology expired. We have 
since returned to the same levels, primarily because of a patent from Sherrie 
Morrison, Vernon Oi, and Leonard Herzenberg used in the production of monoclo-
nal antibodies. That patent expires in 2015. In general, very few technologies bring 
in much income. At Stanford, we feel we have had three big technology transfer 
hits—recombinant DNA, Google, and functional antibodies—since our inception 
in 1970. This is out of the over 9,000 invention disclosures we have received. 
Naturally we hope our next big hit is already percolating among the more recent 
disclosures. 
 OTL remains self-sustaining from its 15% of gross revenue. Our operating bud-
get in FY2011 was $5.4 million. The left-over from the 15% after our budget is 
covered is returned to the university. Some of this has been used to help fund the 



























 Fig. 7.1  Stanford’s income from royalties,  fi scal years 1970–2011 
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Monies have also been given to the Research & Graduate Fellowship Fund for 
graduate student fellowships at Stanford. Figure  7.2 shows the comparison of our 
budget versus the 15% over time. 
 For information on other universities’ statistics, the AUTM annual licensing sur-
veys can be consulted  [ 3 ] . 
 5  Factors That Help OTL Succeed 
 A number of factors help OTL succeed in transferring technologies that will bene fi t 
society. 
 First, we try to be facilitators. Our job is part of a transition team for the technol-
ogy to make its way from academia to industry. There are certain rules we need to 
follow (the Stanford policies and ethical practices), but we work within those guide-
lines to  fi nd solutions to shepherd technologies into their new homes for further 
growth. We try to avoid being a roadblock whenever possible. 
 As part of our role to foster innovation through technology licensing at Stanford, 




























 Fig. 7.2  Stanford’s OTL’s income (15%) versus its operating expenses over time. The difference 
goes back to the university to support research and education 
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many of the groups around campus that work with entrepreneurs and potential 
entrepreneurs. Once a year, the group puts together “eWeek,” a week spotlighting 
entrepreneurship around campus. Most members of SEN put on an event during the 
week that highlights the group’s focus. In 2012, OTL had an open house that dis-
played and discussed particular inventions. 
 Second, we strive to be reasonable in how we handle our technologies, including 
the  fi nancial terms of the licenses. We want a fair deal. If the company does well, 
then we do well. 
 Third, we try to “plant as many seeds as possible,” meaning we work on getting 
as many technologies out to industry or other developers as possible. Going back to 
the  fi rst point, we do not want to be a roadblock. We market all of our technologies 
to industry in the attempt to  fi nd a licensing partner. Still, our best leads for licens-
ing are often through some sort of connection from our inventors. For quite a while 
now, we have been licensing around 20–25% of our invention disclosures. We think 
this is a good number considering the early stage of the technologies. Naturally we 
would like for it to be higher. 
 Fourth, we are fairly ef fi cient. We have processes and license templates in place 
that we have worked on for decades. We do make changes to increase our productiv-
ity, including developing a core group of marketing people, continually updating 
our database, revising and improving our boilerplate agreements, and standardizing 
our option agreement terms and  fi nancials. When negotiating a license agreement, 
if we have not worked with the licensing party before, we let them know upfront 
which clauses we cannot change because of policies and guidelines. This can save 
everyone a lot of time trying to negotiate sections that do not have any wiggle 
room. 
 Startups in particular are sensitive to timing. If they have an eager investor, a 
startup may need to react quickly to mirror the enthusiasm of the investor to the 
opportunity. We will work with startups and investors on their schedules whenever 
possible. 
 Fifth, we want our licenses to be the start or the continuation of a long-term rela-
tionship with the licensing company. Through the license, we are allowing access to 
a Stanford asset (a researcher’s “baby”) and having the company nurture it into the 
success we all hope it will be. Like a report card from a child, we want to be kept 
informed of its progress. If there are any issues, we want to know about them early 
and work with the company on those issues before they become immense problems. 
But if the asset needs to return to Stanford, it is good for us to know it is coming and 
to prepare for what Stanford will then do with the technology. 
 Under the licenses, Stanford not only asks for yearly progress reports, but that 
developmental milestones be met. If a company isn’t pursuing the technology, 
Stanford can terminate the agreement and  fi nd another partner to develop the tech-
nology. This is the option of last resort, but does need to remain an option because 
our mission is to have the technologies eventually bene fi t society. Our hope is that 
the partnership leads to repeat customers. Even if the  fi rst license doesn’t yield a 
commercial outcome, we aim for all parties—the university, the researchers, and the 
company—to view the experience positively. 
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 Finally, we seek to create an innovative environment. Stanford makes OTL’s job 
easier by having an atmosphere where people want to create and often are willing to 
work together. People here want to solve problems and want to see those solutions 
disseminated. 
 An example of this is Bio-X. Opened in 2003, the center houses faculty and 
researchers from various disciplines in open laboratories to work on problems in 
biology and medicine. For example, a  fl oor of the building could have researchers 
from mechanical engineering, statistics, and microbiology. More than just provid-
ing space, the program offers some funding mechanisms, interdisciplinary educa-
tion, and potential to work with industry. 
 Connections are key to getting almost anything off the ground. Many of the 
researchers and business people on campus are already well connected. Others sim-
ply ask their neighbors for help. If someone needs help with connections, whether 
for potential  fi nancing, partners, or space for their startup, we can direct them to 
resources. 
 Stanford also has many resources for education regarding creating new technolo-
gies and starting a new business. There are formal courses but also workshops, 
groups, and programs in these areas. Examples include the Stanford Biodesign 
Program, the Stanford Technology Ventures Program, and the Center for 
Entrepreneurial Studies. 
 The resources that help sustain and grow our innovative environment have 
increased over the years. Some have blossomed while others have faded away. 
A program that has become particularly strong is SPARK, “an innovative, cost-effective 
way to overcome the hurdles associated with translating academic discoveries into 
drugs or diagnostics that address real clinical needs  [ 5 ] .” SPARK was started by 
Stanford faculty member Daria Mochly-Rosen in response to the need she saw at 
Stanford after she started her own company. 
 The SPARK mission is twofold:
 1.  To help academicians overcome the obstacles involved in moving research inno-
vations from bench to bedside; and 
 2.  To educate faculty, postdoctoral fellows, and graduate students on the transla-
tional research process and path to clinical application so that development of 
promising discoveries becomes second nature within our institution. 
 SPARK provides funding to select projects to translate them from basic research 
to more advanced stages where industry is more likely to pursue them. They also 
educate, mentor, and advise the grantees and all other interested academicians on 
this translational research process. A recent Nature Medicine article noted that 
about half of SPARK’s projects have been taken up by commercial companies, and 
that other institutions are looking at SPARK’s model  [ 6 ] . 
 Another program at Stanford that offers small amounts of proof-of-concept fund-
ing is the birdseed program. The program offers up to $25,000 in further funding for 
technologies that have already been disclosed to and marketed by our of fi ce, but that 
just need a bit of extra work to make them more attractive for licensing by 
industry. 
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 6  Working with Startups 
 As a part of the innovation cycle, university technology transfer organizations work 
with startups. Many of the startups have inventor/research involvement, but some do 
not. For example, sometimes entrepreneurs-in-residence from local venture capital 
 fi rms look around the university for opportunities to start their next business. 
 However, most Stanford startups do have some sort of inventor involvement. In 
these cases, con fl ict of interest issues are of primary concern. The university 
addresses these licensing con fl ict of interest issues by a multi-step process that often 
begins with a con fl ict of interest memo provided by OTL. In the memo, OTL 
describes the technology under consideration for license, the interested company, 
and some particulars of the potential license. The group reviewing the con fl ict then 
meets with the affected researcher and a plan is devised, if needed, on how the 
researcher’s work with the company will be separate from the work occurring or to 
occur at Stanford. Of particular importance in this review is how any student might 
be affected by the researcher’s relationship with the company. Once this plan is 
worked out, the con fl ict of interest review group contacts OTL on whether it can 
proceed with the license. The review group continues to maintain oversight of the 
potential con fl icts. 
 When negotiating the license agreement, OTL will typically not negotiate with 
the inventor unless the inventor has left the university. The inventor is in a con fl icted 
situation, and because the inventor receives partial remuneration from the licensing 
process, OTL asks that the company have a non-inventor negotiate the license. 
 Startups sometimes  fi rst take option agreements when licensing. These options 
usually last 6–12 months and are simple agreements that require little negotiation. 
During the option period, the startup is looking for money or may be doing some 
proof-of-concept experiments. For an exclusive option, the university is not allowed 
to license the technology to any other company. If the company succeeds in what-
ever it was trying to accomplish during the option period, it then “exercises” the 
option to begin negotiation of the full license agreement. 
 Some of the areas we look at closely when negotiation these licenses are:
 1.  Upfront payment—This is usually a combination of cash and equity. We often 
take equity in any startup to which we exclusively license a technology. How 
much equity Stanford receives is balanced against the other  fi nancial consider-
ations in the license. Some startups are more  fl exible on equity than others, which 
often depends on their sources of capital. 
 2.  Annual payments—Because startups are cash-poor, annual minimums may be 
lower in earlier years and ramp up over time and after certain milestones. 
 3.  Diligence—Any exclusive license has diligence, but this can sometimes be a 
moving target, particularly with startups. We  fi nd solutions that work for our 
need for strong diligence and the company’s changing business plan, taking into 
account vicissitudes of the economy. For example, we may agree to certain dili-
gence over the  fi rst 5 years of the license agreement and then will reconvene in 
5 years to determine the next set of milestones. 
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 4.  Milestone payments—Because the upfront and other early payments are usually 
low, we try to counterbalance some of this with somewhat higher payments, 
including product milestones, later in the development cycle. 
 5.  Sublicensing—Many startups will sublicense the technology. For example, when 
licensing a therapeutic to a startup, the startup knows that it will not likely be 
able to take the potential product through clinical trials on its own and therefore 
will have to partner. The partnering often includes sublicensing. Depending on 
when the sublicensing occurs, OTL will receive some part of the remuneration 
received by the startup from the sublicensing partner. Often the amount is scaled 
down over time as the company invests more of its own effort and money into the 
technology. 
 When working with startups, as with any company, we want them to succeed. 
Their success is our success. Many startups are run by new entrepreneurs, so we try 
to help where possible. First, we understand that startups are cash-poor. We try to 
make our licenses affordable, but the startup needs to have some skin in the game 
and some ability to raise money. When working on our license agreement, we advise 
the startup where we can be  fl exible and where our policies do not allow us much, 
if any, wiggle room. Startups sometimes hire attorneys to assist them with their 
license negotiations. Although a good idea, sometimes the attorneys can be overly 
ambitious and cost the company a lot of money negotiating points that are insub-
stantial or non-negotiable. The startups sometimes need to differentiate an impor-
tant point to pursue and where they can also be more  fl exible. 
 Second, we renegotiate more with startups than with other entities. As mentioned 
above, startups are ever evolving, sometimes even when they are past the true startup 
phase. We recognize that their needs and capabilities might change over time. Many 
times events occur that are not anticipated by the license. Our end goal remains the 
same—products that bene fi t society—so if that is being met, we can often work out 
a solution to the company’s concerns on the license. 
 7  Symbiosis 
 Professor Terman had a vision of “close ties between Stanford students and the 
emerging technology industries  [ 7 ] ,” and the fostering of this vision helped create 
the Silicon Valley of today. Stanford continues to see this as a great symbiotic rela-
tionship. Stanford is bordered by Page Mill and Sand Hill roads, homes to venture 
capital  fi rms, the Stanford Research Park, and attorney  fi rms. Stanford provides 
education to students who go to work at local companies or start their own. Stanford 
researchers create revolutionizing innovations that might be part of those same 
companies. 
 This synergistic relationship goes beyond these areas as well, helping Stanford to 
sustain and improve its amazing capabilities. As noted by President John Hennessy 
in a recent Fortune online interview [ 8 ]:
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 …think of the most money you could have charged Hewlett and Packard for their little 
discovery that they took out and started a company with, think of the most money. Multiply 
by 100,000 times and you’ll begin to get an idea of the scale of their philanthropy to the 
university over many years. 
 So, we believe in that symbiotic relationship, we believe that if we’re good to people they’ll 
give back, and we can make something that works, and we won’t be inhibiting the  fl ow of 
technology, which I think is a really crucial thing, because in the end that’s our long term 
contribution to society . 
 Stanford strives to keep this mutually bene fi cial relationship functioning and 
energized. OTL is one element in a long equation of factors that may produce the 
next cancer therapeutic or alternative energy solution. The better each factor works 
and works together with the other factors, the greater the likelihood of a positive 
outcome. 
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